POAI Insider Trading Activity and SEC Form 4 Filings
POAI insider trading summary
No open-market insider purchases or sales of Predictive Oncology Inc. (POAI) have been reported on SEC Form 4 in the past 12 months.
Latest POAI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 25, 2023 | Charles Lee Nuzum Sr | Director | Sell | $30K (10,000 @ $3.04) |
| Dec 15, 2022 | Daniel E Handley | Insider | Buy | $2K (6,000 @ $0.41) |
| Dec 2, 2022 | Raymond F Vennare | Insider | Buy | $207 (400 @ $0.52) |
| Dec 2, 2022 | Raymond F Vennare | Insider | Buy | $2K (4,600 @ $0.52) |
| Dec 2, 2022 | Robert L Myers | Chief Financial Officer | Buy | $5K (8,795 @ $0.57) |
| Nov 29, 2022 | Daniel E Handley | Insider | Buy | $4K (10,000 @ $0.36) |
| May 26, 2022 | Daniel E Handley | Insider | Buy | $955 (2,550 @ $0.37) |
| May 25, 2022 | Daniel E Handley | Insider | Buy | $980 (2,800 @ $0.35) |
| May 24, 2022 | J Melville Engle | Insider | Buy | $59K (159,500 @ $0.37) |
| May 20, 2022 | Robert L Myers | Chief Financial Officer | Buy | $5K (16,125 @ $0.30) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.